Board of Directors

Our Board of Directors comprises industry veterans who provide expert insights and guidance to AgeneBio.

Charles Clarvit
Chairman of the Board

Charles Clarvit has served as a member of our Board of Directors since December 2013. Mr. Clarvit is CEO of his family office Clarvit Capital. Prior to that, he was CEO of Vinci Partners US and a former Managing Director and Co-Head of BlackRock Alternative Advisors, the firm’s fund of funds platform. He joined BlackRock in 2007 following acquisition of the fund of funds business of Quellos Group, LLC. At Quellos he served as Principal and oversaw the Quellos Client Group. Previously, he was a Managing Director with CIBC Oppenheimer & Co., responsible for alternative investment strategies. He is also on the Johns Hopkins Center for Financial Economics Advisory Board and a Trustee on the Board of Johns Hopkins University. He earned a bachelor’s degree in Social and Behavioral Sciences with a concentration in Economics and Statistics from the Johns Hopkins University in 1978.

Darryle Schoepp, Ph. D. 

Dr. Schoepp has over thirty years experience in the discovery and development of innovative Neuroscience therapeutics in the pharmaceutical industry. This includes 20 years at Eli Lilly as a scientist and leader of the Neuroscience research department, and 12 years at Merck as the Neuroscience research therapeutic area leader. At. Merck his team built a pipeline of innovative first class agents for Alzheimer’s disease, Parkinson’s disease, pain/migraine, and schizophrenia. His group made important contributions to the pioneering trials of the BACE inhibitor verubecestat in prevention trials for Alzheimer’s disease and developed the tau PET imaging agent MK-6420.

Dr. Schoepp has over 200 publications and is an inventor of 15 US patents. He is recognized for having made major contributions in the investigation of glutamate receptor pharmacology and therapeutics with the discovery of novel first in class agents for psychiatric and neurological diseases. Schoepp’s honors include the 2002 Pharmacia / ASPET Award for Experimental Therapeutics for his research on the experimental therapeutics of metabotropic glutamate receptors in psychiatry, and 2007 Ray Fuller / ASPET Lecturer in Neurosciences in recognition of translational pharmacology work in the glutamate field.

Dr. Schoepp received his bachelor’s degree in Pharmacy from North Dakota State University and his doctoral degree in Pharmacology and Toxicology from West Virginia University.

Michela Gallagher, PhD
Founder and CEO

Michela Gallagher, PhD, founded AgeneBio in 2008 and serves as CEO. Dr. Gallagher is the Krieger-Eisenhower Professor of Psychological and Brain Science and heads the Neurogenetics and Behavior Center at Johns Hopkins University. She is a Fellow of the American Psychological Association, the American Psychological Society and the American Association for the Advancement of Science. She has spent 20 years researching memory and learning as well as the neurobiology of aging, having published more than 250 peer-reviewed papers, and brings this expertise to the company as it seeks to advance discoveries to address amnestic mild cognitive impairment and Alzheimer’s disease. She has served the on Boards of Scientific Counselors at the National Institute of Mental Health and the National Institute on Aging, the Scientific Advisory Board of the Stanley Center at the Broad Institute and the Advisory Board of DZNE, the German Center for Neurodegenerative Diseases.

Prior to joining Johns Hopkins in 1997, Dr. Gallagher rose through the faculty ranks at University of North Carolina at Chapel Hill, where she was the Kenan Professor of Psychology. She earned her PhD in Physiological Psychology from University of Vermont.

Ronald M. Nordmann

Ronald M. Nordmann has served as a member of our Board of Directors since September 2013. Mr. Nordmann is a private investor and spent 23 years on Wall Street as a financial analyst, primarily with PaineWebber, Inc., and Oppenheimer & Co., Inc., focusing on the pharmaceutical and biotechnology industries. During his career on the Street, he participated in numerous investment banking transactions. Mr. Nordmann was a partner at Deerfield Management, a healthcare hedge fund. Since retiring in 2000, he devoted his time to corporate governance. Mr. Nordmann sat on the boards of directors of 10 public and private pharmaceutical companies in three countries. Mr. Nordmann is an Emeritus Trustee of Johns Hopkins and sits on the boards of several not-for-profit community organizations including the American Red Cross. He received an undergraduate degree from Johns Hopkins University and an MBA from Fairleigh Dickinson University.

Rod Dowler

Rod Dowler is an experienced business adviser, executive and business angel who is Chair/CEO of the Industry Forum, a London based business policy forum which has many major international members. He is a former KPMG Consultancy partner and a fellow of the Institute of Physics. After graduation from Oxford in Physics he worked extensively in the financial and technology sectors, and on a range of engagements for the European Commission. He was a partner at KPMG for 15 years where he led a rapid expansion of the KPMG European High Technology Practice and gained international experience in North America, Europe and Asia. One highlight for him was working with Regis McKenna, the Palo Alto marketing guru who advised Steve Jobs at Apple. He has experience in large outsourcing deals and as a business angel he has assisted small technology companies with business planning and raising finance.